A federal advisory panel voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is non-mandatory. The FDA has given no word on whether it will act on the guidance. The move came after weeks of stakeholder sessions. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have weak safety evidence or help for most uses. The call could shift how the agency handles a part of the wellness market that is moving at speed. Market observers are watching to see if the FDA picks up the plan. A spokesperson for the regulator offered no set date for a follow-up. Supporters argue the change would expand access to products that users favor. Critics warn that looser rules could leave gaps in oversight across a fast-moving market. The committee vote only sets up a possible shift, and the final decision rests with the agency.